- Clinical Trials
- April 2024
- 220 Pages
Global
From €2377EUR$2,500USD£2,039GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,631GBP
- Clinical Trials
- April 2024
- 550 Pages
Global
From €4753EUR$5,000USD£4,077GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,631GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,631GBP
- Clinical Trials
- April 2024
- 210 Pages
Global
From €2377EUR$2,500USD£2,039GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,631GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2377EUR$2,500USD£2,039GBP
- Drug Pipelines
- April 2024
- 50 Pages
Global
From €1426EUR$1,500USD£1,223GBP
- Clinical Trials
- April 2024
- 70 Pages
Global
From €1426EUR$1,500USD£1,223GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,223GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1426EUR$1,500USD£1,223GBP
- Report
- January 2024
- 182 Pages
Global
From €4658EUR$4,900USD£3,996GBP
- Report
- November 2023
- 175 Pages
Global
From €4658EUR$4,900USD£3,996GBP
- Report
- October 2023
- 190 Pages
Global
From €4658EUR$4,900USD£3,996GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,384GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,384GBP
- Report
- July 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,569GBP
- Report
- October 2023
- 161 Pages
Global
From €2377EUR$2,500USD£2,039GBP
- Report
- January 2024
- 425 Pages
Global
From €3422EUR$3,600USD£2,936GBP
Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more